Department of Surgery, Loyola University Medical Center, Maywood, IL; Loyola University Chicago Stritch School of Medicine, Maywood, IL.
Department of Surgery, Loyola University Medical Center, Maywood, IL; Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL.
Surgery. 2024 Mar;175(3):695-703. doi: 10.1016/j.surg.2023.08.040. Epub 2023 Oct 18.
Prior studies of fragmentation of care in pancreatic cancer have not adjusted for indicators of hospital quality such as Commission on Cancer accreditation. The effect of fragmentation of care has not been well defined.
We queried the National Cancer Database to identify patients undergoing pancreaticoduodenectomy and distal pancreatectomy with perioperative systemic therapy for clinical stages I-III pancreatic cancer between 2006 and 2019. Patients who received systemic therapy at a center different than the center performing surgery were categorized as having fragmentation of care. Patients having fragmentation of care were further categorized on the basis of whether (fragmentation of care Commission on Cancer) or not (fragmentation of care non-Commission on Cancer) systemic therapy was administered at a facility accredited by the Commission on Cancer.
A total of 11,732 patients met inclusion criteria; 5,668 (48.3%) underwent fragmentation of care, and 3,426 (29.2%) fragmentation of care non-Commission on Cancer. Patients undergoing fragmentation of care non-Commission on Cancer were less likely to receive neoadjuvant systemic therapy than those undergoing fragmentation of care Commission on Cancer or non-fragmented care (27.7% vs 40.1% vs 36.8%, P < .001). On Cox analysis, advanced age, comorbid disease, node-positive disease, and facility type were associated with risk of overall survival. Fragmentation of care was not (adjusted hazard ratio = 0.99, 95% confidence interval [0.94-1.06], P = .8). On Kaplan-Meier analysis, there were no significant differences in 5-year overall survival between treatment cohorts.
In patients undergoing fragmentation of care for localized pancreatic cancer, those treated with systemic therapy in Commission on Cancer accredited facilities are more likely to be given neoadjuvant therapy but demonstrate no significant improvement in survival relative to those undergoing non-fragmented care or those undergoing fragmentation of care but receiving systemic therapy in nonaccredited facilities.
先前关于胰腺癌治疗碎片化的研究并未调整癌症委员会认证等医院质量指标。治疗碎片化的效果尚未得到明确界定。
我们查询了国家癌症数据库,以确定 2006 年至 2019 年间接受手术治疗联合围手术期全身治疗的 I-III 期胰腺癌患者。在手术中心之外的中心接受全身治疗的患者被归类为治疗碎片化。根据是否(癌症委员会认证的治疗碎片化)或未(非癌症委员会认证的治疗碎片化)在癌症委员会认证的机构接受全身治疗,将接受治疗碎片化的患者进一步分类。
共有 11732 名患者符合纳入标准;5668 名(48.3%)患者接受治疗碎片化,3426 名(29.2%)患者接受非癌症委员会认证的治疗碎片化。接受非癌症委员会认证的治疗碎片化的患者接受新辅助全身治疗的比例低于接受癌症委员会认证的治疗碎片化或非碎片化治疗的患者(27.7% vs. 40.1% vs. 36.8%,P <.001)。在 Cox 分析中,高龄、合并症、阳性淋巴结疾病和医疗机构类型与总生存风险相关。治疗碎片化与总生存风险无关(调整后的危险比=0.99,95%置信区间[0.94-1.06],P=.8)。在 Kaplan-Meier 分析中,各治疗队列的 5 年总生存率没有显著差异。
在接受局部胰腺癌治疗碎片化的患者中,在癌症委员会认证机构接受全身治疗的患者更有可能接受新辅助治疗,但与非碎片化治疗或在未认证机构接受全身治疗但接受治疗碎片化的患者相比,生存获益没有显著改善。